Molcef Plus Film Coated Tablet 200 Mg

Molcef Plus Film Coated Tablet 200 Mg is a combination antibiotic medication that contains Cefixime and Clavulanic Acid as active ingredients. This pharmaceutical formulation is primarily marketed in Turkey and some other regions for treating various bacterial infections. The synergistic combination of these two active compounds provides enhanced antimicrobial efficacy against a wide range of pathogens, including those that have developed resistance to standard antibiotics.

This article provides detailed information about the composition, pharmacological properties, therapeutic applications, dosage guidelines, and safety considerations associated with Molcef Plus.

Composition

Each film-coated tablet of Molcef Plus contains 223.815 mg of Cefixime Trihydrate equivalent to 200 mg of anhydrous Cefixime and 297.876 mg of Potassium Clavulanate equivalent to 125 mg of Clavulanic Acid in a 1:1 ratio. The medication also contains various excipients including lecithin (soya) at 0.455 mg and other pharmaceutical necessities that contribute to the stability and bioavailability of the active ingredients. The film coating provides protection from environmental factors and facilitates easier swallowing of the tablet.

Pharmacological Properties

Pharmacodynamics

Molcef Plus combines the antimicrobial action of two distinct compounds. Cefixime is a third-generation cephalosporin antibiotic with marked bactericidal activity against various Gram-positive and Gram-negative organisms. It works by inhibiting bacterial cell wall synthesis through binding to one or more of the penicillin-binding proteins (PBPs), which are essential for bacterial cell wall formation.

This action results in bacterial cell lysis and death. Clavulanic Acid, on the other hand, is a beta-lactamase inhibitor with minimal intrinsic antibacterial activity. Its primary function is to protect Cefixime from degradation by beta-lactamase enzymes produced by resistant bacteria, thereby extending the spectrum of activity of Cefixime against many resistant strains.

Pharmacokinetics

The absolute oral bioavailability of Cefixime ranges from 22% to 54%. Notably, food does not significantly affect the absorption of Cefixime, allowing for flexible administration with respect to meals. Once absorbed, Cefixime is distributed throughout the body tissues and fluids. The presence of Clavulanic Acid enhances the effectiveness of Cefixime by inhibiting beta-lactamases that would otherwise degrade the antibiotic.

The medication reaches therapeutic serum concentrations within a few hours of administration and is primarily excreted through renal pathways. Patients with impaired kidney function may require dosage adjustments to prevent drug accumulation.

Therapeutic Indications

Molcef Plus is indicated for the treatment of infections caused by susceptible bacteria in various body systems. According to clinical data, this combination is effective against a broad spectrum of pathogens and is prescribed for the following conditions:

Upper Respiratory Tract Infections

The medication is efficacious in treating pharyngitis, tonsillitis, otitis media (middle ear infection), and sinusitis caused by susceptible organisms including Streptococcus pyogenes, Haemophilus influenzae (beta-lactamase positive and negative), and Moraxella catarrhalis.

Lower Respiratory Tract Infections

Molcef Plus has demonstrated effectiveness against acute pneumonia, acute bronchitis, and exacerbations of chronic bronchitis. The drug targets pathogens such as Streptococcus pneumoniae and Haemophilus influenzae that commonly cause these conditions.

Urinary Tract Infections

The medication is prescribed for treating urinary tract infections including acute cystitis, cysto-urethritis, and uncomplicated acute pyelonephritis caused by bacteria such as Escherichia coli and Proteus mirabilis.

Sexually Transmitted Infections

Molcef Plus is effective against uncomplicated gonorrhea caused by Neisseria gonorrhoeae, including both penicillinase-producing and non-penicillinase-producing strains.

Mechanism of Action

The dual-action mechanism of Molcef Plus makes it particularly effective against a wide range of bacterial infections:

1. Cefixime: As a third-generation cephalosporin, Cefixime inhibits bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located on the bacterial cell wall. This binding disrupts the final transpeptidation step of peptidoglycan synthesis, preventing cell wall formation and leading to bacterial cell lysis and death.

2. Clavulanic Acid: This compound functions as a beta-lactamase inhibitor by binding irreversibly to beta-lactamase enzymes produced by resistant bacteria. By inactivating these enzymes, Clavulanic Acid prevents the degradation of Cefixime, allowing the antibiotic to reach its target site and exert its bactericidal effect even against beta-lactamase-producing organisms.

This synergistic combination provides enhanced efficacy against many bacterial strains that would otherwise be resistant to Cefixime alone, significantly broadening the spectrum of antimicrobial activity of the medication.

Dosage and Administration

The appropriate dosage of Molcef Plus varies depending on the severity of infection, patient age, weight, and renal function. Below are general dosage guidelines:

Adult Dosage

For most infections, the recommended adult dosage is 200-400 mg daily according to the severity of infection, administered either as a single dose or divided into two equal doses taken 12 hours apart. For uncomplicated gonorrheal infections, a single oral dose of 400 mg is typically recommended.

Pediatric Dosage

For children over 10 years of age or weighing more than 50 kg, the adult dosage is recommended. For younger children, dosing is typically weight-based at approximately 8 mg/kg/day, administered either once daily or divided into two doses. For children under 10 years, the oral suspension form may be more appropriate than tablets.

Dosage in Renal Impairment

For patients with impaired renal function, dose adjustment is necessary. Normal dosage can be administered to patients with creatinine clearance of 60 mL/min or higher. For patients with creatinine clearance between 21-60 mL/min, 75% of the standard daily dose is recommended. When creatinine clearance is below 20 mL/min, the dose should be reduced to 50% of the standard daily dose.

Administration Guidelines

Molcef Plus tablets should be swallowed whole with sufficient water. Taking the medication at the beginning of meals is recommended to enhance absorption. The usual course of treatment is 7 days, but this may be extended to 14 days depending on the nature and severity of the infection.

Contraindications

Molcef Plus is contraindicated in the following conditions:

• Known hypersensitivity to Cefixime, other cephalosporins, or any component of the formulation

• History of severe immediate hypersensitivity reactions (e.g., anaphylaxis) to beta-lactam antibiotics

• Previous history of cephalosporin-associated hemolytic anemia

Caution should be exercised in patients with a history of penicillin allergy due to potential cross-sensitivity between penicillins and cephalosporins.

Side Effects

Like all medications, Molcef Plus may cause side effects, although not all patients experience them. The most commonly reported adverse reactions include:

Common Side Effects

• Diarrhea (most frequent)

• Nausea and vomiting

• Abdominal pain and indigestion

• Headache

• Flatulence and bloating

Less Common Side Effects

• Skin rashes, itching, and other allergic manifestations

• Transient elevations in liver enzymes

• Changes in blood counts (rare)

• Dizziness

• Fever

Rare but Serious Side Effects

• Severe allergic reactions (anaphylaxis)

• Severe skin reactions

• Clostridium difficile-associated diarrhea

• Blood disorders such as hemolytic anemia, thrombocytopenia, or leukopenia

• Kidney problems

Patients should seek immediate medical attention if they experience severe, persistent diarrhea, signs of allergic reaction, unusual bleeding or bruising, or yellowing of the skin or eyes.

Drug Interactions

Molcef Plus may interact with certain medications, potentially affecting its efficacy or increasing the risk of side effects:

Significant Interactions

1. Carbamazepine: Concurrent administration may lead to elevated carbamazepine levels, requiring monitoring of drug levels.

2. Chloramphenicol: In vitro antagonism has been observed between cephalosporins and chloramphenicol; combined therapy should be avoided.

3. Nifedipine: May increase the oral bioavailability of Cefixime through higher maximum concentration (Cmax) and area under the curve (AUC).

4. Probenecid: Can increase Cmax and AUC of Cefixime while decreasing renal clearance and volume of distribution.

5. Salicylates: Administration of aspirin with Cefixime may decrease Cmax and AUC of Cefixime by 20-25%.

6. Warfarin and other anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when Cefixime is given concomitantly.

Laboratory Test Interactions

Molcef Plus may interfere with certain laboratory tests, potentially causing:

• False-positive reactions for ketones in urine with tests using nitroprusside

• False-positive Coombs’ test

• False-positive reaction for glucose in urine when using Clinitest, Benedict’s solution, or Fehling’s solution

Special Populations

Pregnancy and Lactation

The safety of Molcef Plus during pregnancy has not been fully established. It should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Similarly, caution should be exercised when administering Molcef Plus to nursing mothers, as limited data exist regarding its excretion into human milk.

Elderly Patients

Elderly patients may receive the same dosage as recommended for adults. However, renal function should be assessed, and dosage adjustments may be necessary in cases of severe renal impairment.

Pediatric Use

Safety and efficacy have not been established in children less than 6 months of age. For children older than 6 months, dosage should be adjusted according to age, weight, and severity of infection.

Patients with Hepatic Impairment

No specific dosage adjustment is generally required for patients with hepatic impairment unless there is concurrent renal dysfunction.

Storage and Handling

Molcef Plus should be stored at a temperature of 20-25°C (68-77°F) in a dry place, protected from light and moisture. The medication should be kept out of reach of children. Any expired or unused medication should be disposed of properly according to local regulations.

Summary Table